Please select the eligibility criteria that correspond to the clinical trial below.
Title: Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy
Brief Summary: The purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. The patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. Both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.The investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.


Options:
A: Inclusion Criteria:

* Participants must be undergoing treatment for moderate to severe mental health problems.
* Participants must have an expressed desire to work.
* Participants must have sufficient Norwegian reading and writing skills.

Exclusion Criteria:

* Participants are not undergoing treatment for moderate to severe mental health problems.
* Participants do not have an expressed desire to work.
* Participants do not have sufficient Norwegian reading and writing skills.
B: Inclusion Criteria:

* A primary diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic features.
* Depressive symptoms for at least 30 days before the screening visit.
* Outpatient men and women at least 18 years of age.

Exclusion Criteria:

* Significant risk of suicide based on clinical judgment, including common suicidal thoughts and suicide having been considered as a possible solution even without specific plans or intent.
* Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that might confound the study or put the subject at greater risk during study participation.
* Current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder; b) current (within 12 months before baseline) generalized anxiety disorder, panic disorder, or social anxiety disorder; c) presence (within 12 months before baseline) of a clinically important personality disorder as assessed during the psychiatric assessments.
C: Inclusion Criteria:

* Inpatient treatment
* Private internet access
* Informed consent
* Age between 18 and 65 years
* Knowledge of the German language
* Score in the BDI-II \> 13 and clinical diagnosis of a depression (ICD-10: F32.x, F33.x, F34.1, F43.2) verified by the inpatient therapist

Exclusion Criteria:

* Psychosis
* Current alcohol or drug dependency
* Borderline, antisocial, schizoid or schizotypal personality disorder
* Anorexia nervosa
* Life time diagnosis of a schizophrenia, schizoaffective , bipolar oder organic psychic disorder
D: Inclusion Criteria:

* Outpatients
* Sexually active women participating in the study must use a medically acceptable form of contraception
* Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria:

* Treatment with DVS-233 SR at any time in the past
* Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
* Known hypersensitivity to venlafaxine (IR or ER)

Answer: C